Health Canada approves 1st GLP-1 daily pill. Here’s who can take it
PositiveHealth
- Health Canada has approved the first once-a-day semaglutide pill, aimed at reducing the risk of heart disease and Type 2 diabetes, marking a significant advancement in diabetes management.
- This approval is crucial for Novo Nordisk, the manufacturer, as it expands their portfolio of GLP-1 medications, potentially increasing market share and addressing the growing demand for effective diabetes treatments.
- However, the recent setbacks in trials for cognitive benefits of semaglutide highlight the complexities and challenges faced by the company, as they navigate both the successes and limitations of their drug offerings.
— via World Pulse Now AI Editorial System